1
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O&apos Brien, Theresa O&apos Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, February 24, 2004: US06696550 (40 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


2
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, Tarran S Jones, Ted A Yednock: Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies. Elan Pharmaceuticals, Crowell & Moring, August 21, 2012: US08246958 (33 worldwide citation)

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host ...


3
Tarran Jones
Paul D Ponath, Douglas J Ringler, S Tarran Jones, Walter Newman, José Saldanha, Mary M Bendig: Humanized immunoglobulin reactive with α4β7 integrin. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, December 12, 2006: US07147851 (32 worldwide citation)

The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In on ...


4
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O&apos Brien, Theresa O&apos Keefe: Recombinant anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, April 27, 2004: US06727349 (29 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


5
Tarran Jones
Gregory J LaRosa, Christopher J Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lando & Anastasi, July 28, 2009: US07566450 (4 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


6
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lowrie Lando & Anastasi, January 6, 2009: US07473421 (4 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


7
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lowrie Lando & Anastasi, October 28, 2008: US07442775 (4 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


8
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lando & Anastasi, July 24, 2012: US08227211 (3 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


9
Tarran Jones
Paul D Ponath, Douglas J Ringler, S Tarran Jones, Walter Newman, José Saldanha, Mary M Bendig: Humanized immunoglobulin reactive with α4β7 integrin. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, July 22, 2008: US07402410

The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for α4β7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for α ...


10